Annovis to Host Corporate Update Webinar on January 28, 2026

Rhea-AI Summary

Annovis (NYSE: ANVS) will host a corporate update webinar on January 28, 2026 at 4:30 p.m. ET featuring President and CEO Maria Maccecchini, Ph.D.. The presentation will review the company’s recent progress, ongoing late‑stage clinical programs in Alzheimer’s and Parkinson’s disease, strategic direction, and upcoming early‑2026 milestones, followed by a live Q&A.

The webinar is open to shareholders, patients, investigators, and other interested parties; participants are encouraged to register via the company registration link and may submit questions in advance to ir@annovisbio.com.

Key Figures

Webinar date January 28, 2026 Scheduled corporate update webinar

Webinar time 4:30 p.m. ET Scheduled corporate update webinar

Market Reality Check

$3.58 Last Close

Volume Price is down 8.47% on volume of 711,907 shares versus a 20-day average of 4,051,909, indicating relatively light trading ahead of the webinar. low

Technical Shares trade above the 200-day MA of 2.36, despite the recent pullback and a close at 3.78.

Peers on Argus 1 Down

Sector peers show mixed moves: one close peer, RADX, is down sharply (about -36.22%), while others like BRNS are up and several are modestly down. With ANVS down 8.47% and limited peer momentum signals, the move appears more stock-specific than broad sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 03	Conference presentation	Positive	+5.4%	Phase 3 Parkinson’s biomarker data presented at Parkinson Study Group meeting.
Nov 24	Conference presentations	Positive	+7.9%	Two CTAD 2025 presentations on buntanetap cognition and Phase 3 AD design.
Nov 18	Regulatory meeting	Positive	+11.2%	FDA Type C meeting scheduled for PDD and reaffirmed alignment on Phase 3 AD.
Nov 17	Biomarker update	Positive	+29.5%	Phase 3 data showing halted cognitive decline and tau biomarker reductions.
Nov 12	Earnings and update	Positive	+15.2%	Q3 2025 financials plus Phase 3 AD progress and new buntanetap PK data.

Pattern Detected

Recent company-specific news, especially clinical and regulatory milestones, has often been followed by positive price reactions.

Recent Company History

Over the last months, Annovis has highlighted clinical and regulatory momentum around buntanetap in Parkinson’s and Alzheimer’s disease. On Nov 12, 2025, it reported Q3 results with $15.3M in cash and operational runway to Q3 2026, alongside activation of 84 Phase 3 AD sites. Subsequent updates on biomarker data, FDA meeting plans, and major conference presentations (CTAD and Parkinson Study Group) each coincided with positive one-day price moves, showing the market’s sensitivity to clinical progress. Today’s webinar announcement fits into this ongoing communication cadence.

Market Pulse Summary

This announcement schedules a corporate update webinar for January 28, 2026 at 4:30 p.m. ET, where management plans to discuss recent progress, ongoing clinical programs, and strategic direction. In recent months, Annovis has reported Phase 3 biomarker data, FDA meeting plans, and Q3 2025 results that extended cash runway to Q3 2026. Investors may focus on how the webinar contextualizes these developments, clarifies timelines for pivotal trials, and addresses previously disclosed going‑concern language and funding plans.

Key Terms

Alzheimer's disease medical

"therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's"

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

Parkinson's disease medical

"therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's"

A progressive brain disorder in which nerve cells that produce the chemical dopamine gradually die, leading to tremors, slowness of movement, stiffness and balance problems. Think of it like the gradual wearing down of the brain’s movement-control circuitry. It matters to investors because prevalence, treatment advances, diagnostic tests, medical-device approvals and care costs shape demand and revenue prospects for drug developers, device makers and healthcare providers, and clinical trial or regulatory news can move stock prices.

AI-generated analysis. Not financial advice.

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

The webinar will feature Maria Maccecchini, Ph.D., President and CEO, who will provide an overview of the Company’s recent progress, ongoing clinical programs, and strategic directions.

Webinar details

• Date: Wednesday, January 28, 2026
• Time: 4:30 p.m. ET
• Presenter: Maria Maccecchini, Ph.D., President and CEO
• Registration link

“We look forward to beginning the year by sharing a comprehensive update on Annovis with everyone who has been following our journey,” said Maria Maccecchini, Ph.D., President and CEO. “The Company has witnessed strong momentum driven by clinical progress and corporate achievements, with additional milestones expected in early 2026. During this webinar, we will share where we are today, outline our path forward, and engage in direct dialogue with the community.”

The webinar is open to shareholders, patients, investigators, and other interested parties. Participants are encouraged to submit questions in advance by emailing ir@annovisbio.com.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com‍

FAQ

When is the Annovis (ANVS) corporate update webinar and who is presenting?

The webinar is on January 28, 2026 at 4:30 p.m. ET and will be presented by Maria Maccecchini, Ph.D., President and CEO.

What topics will Annovis (ANVS) cover in the January 28, 2026 webinar?

The webinar will cover recent progress, ongoing late‑stage clinical programs in Alzheimer’s and Parkinson’s disease, strategic direction, and expected early‑2026 milestones.

How can shareholders register for the Annovis (ANVS) webinar on January 28, 2026?

Interested parties can register via the company’s registration link provided for the webinar.

Can investors submit questions in advance for the Annovis (ANVS) Q&A session?

Yes. Participants are encouraged to submit questions in advance by emailing ir@annovisbio.com.

Who is the intended audience for the Annovis (ANVS) January 28, 2026 webinar?

The webinar is open to shareholders, patients, investigators, and other interested parties.